Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bronchodilatation test response predictors in lung function assessment of patients with resectable lung cancer and concomitant chronic obstructive pulmonary disease.
J BUON
April 2007
Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Clinic for Pulmonary Oncology, Medical Faculty, University of Novi Sad, Serbia & Montenegro.
Purpose: The goal of this pilot study was to determine factors influencing the bronchodilatation test (BDT) response during preoperative lung function assessment in patients with resectable non-small cell lung cancer (NSCLC) and concomitant chronic obstructive pulmonary disease (COPD).
Patients And Methods: The analysis included 34 patients who met the following entry criteria: preoperative lung function assessment including a BDT, presence of operable, histologically confirmed stage IA-IIIA NSCLC established by computerized tomography (CT) and endoscopical findings, no more than one cardiovascular risk factor present, no interstitial pulmonary diseases (restriction exclusively due to the tumor), and patient's age up to 70 years. The study was partially retrospective and partially prospective.
[Prevalence of COPD in Gdansk sea port workers].
Pol Merkur Lekarski
May 1998
Katedry i Kliniki Chorób Płuc i Gruźlicy Akademii Medycznej w Gdańsku.
Unlabelled: The purpose of the study was to evaluate prevalence of COPD in sea-port workers who has been employed with handling phosphoric compounds, sulphur compounds and grain. Smoking habits has been also analysed. Study group consists of 238 persons working in Gdańsk sea-port.
View Article and Find Full Text PDF[What dosage is sufficient in combined inhalation therapy (fenoterol + ipratropium bromide) in patients with exacerbation of chronic obstructive lung disease?].
Vnitr Lek
July 1998
Oddĕlení TRN FN Motol, Praha.
The authors compared in a prospective study the bronchodilatating and undesirable effects of combined inhalation treatment (phenoterol + ipratropium bromide) in the treatment of patients with exacerbation of chronic obstructive pulmonary disease, using different dosages. The patients were divided at random into two groups--group one inhaled berodual sol 3.5 ml/day (i.
View Article and Find Full Text PDFCOPD: results of long-term treatment.
Wiad Lek
April 1998
Medical Clinic of the Kreiskrankenhaus Siegen, Haus Segen.
During the last decades the life expectation of patients with COPD increased continually. Today the life expectation of these patients reach that of the normal general population. Most important for this effect is the improvement of the therapeutical possibilities.
View Article and Find Full Text PDFTherapeutic equivalence of a novel HFA134a-containing metered-dose inhaler and the conventional CFC inhaler (Berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide. A randomized double-blind placebo-controlled crossover study in patients with asthma.
Respiration
September 1997
Department of Pneumology, De Wever Hospital, Heerlen, The Netherlands.
The efficacy and safety of a novel fenoterol/ipratropium bromide metered-dose inhaler (MDI) formulated with a non-chlorinated propellant, HFA134a, has been compared with placebo and the conventional chlorofluorocarbon (CFC)-containing fenoterol/ipratropium bromide inhaler (Berodual) in asthmatic patients. Fifty-two patients were enrolled in two centres. The fenoterol/ ipratropium bromide treatment produced significantly (P < 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!